Efficacy and Safety of Low Dose, Short Course Eltrombopag in Management of DF and DHF

Abstract

Background: Dengue is the most widespread aedes mosquito borne viral disease which infects more than 50 million people every year. The clinical symptoms of dengue may vary from mild fever to life-threatening incidents. Eltrombopag, a non-peptide, oral TPO-R agonist, small molecular weight is quandaries with the transmembrane domain of a TPO receptor and persuades the Janus Kinase/Signal transducer and activator of transcription pathway, with a significant rise in platelet production.Material & Methods:This study was a cross-sectional observational study which was conducted at Tairunnesa Memorial Medical College and Hospital (TMMCH), Gazipur and Shin Shin Japan Hospital, Uttara, Dhaka. The study was conducted in between July 2021- December 2021. The sample size for this study was 100.Results:The mean age in group 1 was 25±7, in group 2 29±8 and in control group 29±7. The mean Baseline PLT * 109 /L for group 1 was 57±23, for group 2, 51±28 and for control group 54±29. Mean of systolic baseline BP (mmHg) for group 1 was 103.55± 5.04 for group 2 was 105.38±18.34 and for control group was 101.97±8.28 and followed by the mean of diastolic baseline BP (mmHg) was 72.83±6.56, 72.84±12.93 and 71.97±4.75. AEs was found in 4(12.1%) cases of group 1 where in group 2 it was 2(5.9%) and in control group was 3(9.1%). In day 7, the recovery rate of group 1 was 93.9% and in group 2 the recovery rate was 94.1%.Conclusions:Dengue is a vector-borne viral disease which needs medical assistance because it may lead to life-threatening outcome. Eltrombopag can be considered as a therapeutic option to increase the PLT counts in DF and DHF patients in the management of thrombocytopenia.